Birmingham, Alabama -FBI announced a warning about the counterfeit version of the composite weight loss drug, which was found to include “unknown drugs, high levels of impurities, and unsafe or unauthorized drugs.” Such illegal income can lead to serious health problems, including heart problems, camouflage and neurological disorders, and even death.
The warning emphasizes the medical spa, pharmacy and weight loss center claiming that the composite drug contains the active ingredients of the Semaglutide, Ozempic and WEGOVY. The partnership of Safe Medicines has published a report that describes the unauthorized and suspicious ingredients found in countries such as China.
“We’ve seen the meths in fake versions of Ozemic, which will be a fake version. It will cause weight loss, but it’s harmful to health in many ways.” He questioned whether the complex drugs were made in sterile environments and licensed facilities. “Maybe it can also have a vegetation, bacteria that can infect the body. Sterilization is as important as bad ingredients. I don’t know how dangerous the results can be when I get off the drugs you don’t know.
His best advice is to work with a general doctor who fine adjusts of drugs, not remote health, and use complex medicines as the last means.
Dr. David Fieno said, “You really have your life, so your relationship with your doctor is very important. He emphasized the importance of prescription drugs.
He said that as the lack of drug shortages and prices fell, the patient had more options, including cash salary programs and guarantees through Medicare and Medicaid. Dr. Fieno said, “Today we have two common options for patients.
Despite the dramatic story of weight loss and health improvement, many insurance plans are diverse, except for the weight loss range.
Dr. Fieno said, “We have less heart attack, less stroke, and are unlikely to die with drugs,” Dr. Fieno added.
Concerns of FDA for unlawful GLP-1 drugs used for weight loss
Understand this drug that is not approved by this drug
The FDA knows that some patients and medical professionals may be able to lose weight loss options of GLP-1 (GLP-1 (GLP-1) receptor agonist (GLP-1), including Semaglutide and Tirzepatide. Unsolated versions can be dangerous for patients because they are not reviewed by the FDA on safety, efficiency and quality before selling.
FDA recommendation for patients
The patient must receive a prescription from a doctor and fill the prescription in the pharmacy, such as the state.
Visit the FDA’s BESAFERX campaign and buy resources safely online.
If you have any questions about medicines, consult your doctor.
Concerns about the composite version of these drugs
FDA approval drugs cannot meet the medical needs of the patient or if the FDA approval drug is not commercially available, the complex may be appropriate, but the complex drugs are not approved. This means that the agency does not review complex drugs for safety, efficiency or quality before selling the market.
The institution has confirmed some concerns about combined GLP-1 drugs. The FDA is in cooperation with the state regulatory partner and will continue to communicate with the multifunction machine regarding these concerns.
Concerns with complex detailed glue and tir prepared tides
The FDA has received several reports on the side effects that may be related to the administration error related to the composite Semagluide product. This administration error occurred from measuring and managing the wrong dose of the drug and in some cases, and in some cases, medical professionals miscalculate the dose of the drug.
In addition, the organ received a side effect report that could be related to the complex Semaglutide or TIRZEPATIDE product taken more than the FDA approval drug label. This can mean to use more products in a single capacity to take more often or increase the amount faster (appropriate schedule). Some of the side effects are serious and some patients are looking for medical attention to symptoms, including nausea, vomiting, diarrhea, abdominal pain and constipation.
Medical service providers must be wary when prescribing composite semi -glue or tira discipleship products and determining the appropriate capacity and appropriate and medication schedule of the patient. The agency also recommends that the patient talks about how to consult a medical service provider or to measure and administer the capacity of a complex semi -grated or tira discipleship.
Reta Truide cannot be used for complexes.
Retatrutide cannot be used for synthesis according to federal law. It is also not a component of the FDA approval drug and is not found to be safe and effective in any state.
The salt type should not be used to combine three hemp glue tides.
This organization knows that some semagluide products that are sold by the complex may be salt form. Such salt forms, including sodium sodium sodium and semaglutide, are active ingredients that are different from being used for approved drugs. This organ does not have information about whether the salt has the same chemical and pharmacological characteristics as the active ingredient of the approved drug, and we do not know the legal basis for the use of composite use.
Side effects associated with the composite version of Semaglutide and Tirzepatide
The FDA received reports on side effects associated with the combined version of three retail and Tirje fade. However, federal law is likely to store side effects in the composite version of these drugs because the national pharmacy that does not outsourize the facility does not outsourced to submit side effects to the FDA. Many side effects reported on complex products appear to match the side effects related to the FDA approval version of these products.
As of February 28, 2025, the FDA received the following.
More than 455 reports on side effects using composite semaglu tides.
More than 320 reports of side effects using complex TPAIDs.
It is not always possible to always determine whether the side effects have occurred directly by the use of drugs or whether other factors contributed to these side effects.
Version illegally sold of this drug
Counterfeit
The FDA knows about counterfeit Ozempic sold in US counterfeit medicines, but contains wrong ingredients and can contain too much ingredients in too little, too little, too little, or other harmful ingredients.
The agency examines suspicion of suspected drugs to determine public health risks and proper regulatory response. The FDA is bound to protect US drug supply from these threats.
Illegal online sales of this drug
The FDA has filed a letter to monitor the Internet for fraudulent or unsuccessful drugs and stop the distribution of Semaglutide and Tirzepatide, which illegally sold. This illegally sold drug:
Can be a counterfeit
It can include wrong or harmful ingredients
Too little or too much or may not contain any active ingredients at all.
The institution calls for the consumer to be wary when purchasing drugs online and only purchases at License Pharmacy.
The false versions for research purposes are for human consumption.
The FDA is marked as “research purposes” or “not human consumption” to a company that illegally sells illegally approved drugs, including Semaglutide, Tirzepatide or Retatrutide. This product has been sold directly to consumers for human use as a dosing guideline. The agency urges not to buy these products that can be harmful to consumers without quality and health.
We report a problem with the FDA
The FDA recommends that health care professionals, patients and complexes report side effects or quality problems for these drugs or all drugs for the FDA’s drug overceps side effect report program.
Write and submit a Reportonline
Download and complete form and submit it through 1-800-FDA-0178 fax.
Also, contact the CDER Division Division of Druginfo@fda.hhs.gov or 855-543-3784.
